$OTLK Secures Funding to Support ONS-5010 / LYTENAVA™
Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million
announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 35,000,000 shares of common stock of Outlook Therapeutics, at a price to the public of $1.00 per share, less underwriting discounts and commissions.
finance.yahoo.com/news/outlook-therapeutics-increases-previously-announced-045900571.html
Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal
finance.yahoo.com/news/outlook-therapeutics-announces-closing-35-210500916.html
Outlook Therapeutics’ Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Through Planned BLA Submission
The combined net proceeds from these stock offerings are expected to provide sufficient capital to fund operations through the expected filing of the Biologics License Application (BLA) for ONS-5010 for wet age-related macular degeneration (wet AMD), which is planned for the end of calendar 2021.
“Not only have we secured enough capital to significantly extend our cash runway through important upcoming milestones in 2021, but we have provided ourselves with more time to unlock the greatest value and potential for ONS-5010, the company, and our stockholders. We believe we are now in an improved position that will allow us to both maximize the value of this asset and to provide an FDA-approved ophthalmic formulation of bevacizumab to patients.”
Extensive market research indicates that ONS-5010, if approved, will be a significant therapy in the retinal anti-VEGF market, currently estimated to be in excess of $13 billion worldwide.
Clinical Progress of ONS-5010 On Track-
Therapeutics expects to report pivotal safety and efficacy data in the third calendar quarter of 2021.
finance.yahoo.com/news/outlook-therapeutics-recent-financing-secures-140500625.html
announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 35,000,000 shares of common stock of Outlook Therapeutics, at a price to the public of $1.00 per share, less underwriting discounts and commissions.
finance.yahoo.com/news/outlook-therapeutics-increases-previously-announced-045900571.html
Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal
finance.yahoo.com/news/outlook-therapeutics-announces-closing-35-210500916.html
Outlook Therapeutics’ Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Through Planned BLA Submission
The combined net proceeds from these stock offerings are expected to provide sufficient capital to fund operations through the expected filing of the Biologics License Application (BLA) for ONS-5010 for wet age-related macular degeneration (wet AMD), which is planned for the end of calendar 2021.
“Not only have we secured enough capital to significantly extend our cash runway through important upcoming milestones in 2021, but we have provided ourselves with more time to unlock the greatest value and potential for ONS-5010, the company, and our stockholders. We believe we are now in an improved position that will allow us to both maximize the value of this asset and to provide an FDA-approved ophthalmic formulation of bevacizumab to patients.”
Extensive market research indicates that ONS-5010, if approved, will be a significant therapy in the retinal anti-VEGF market, currently estimated to be in excess of $13 billion worldwide.
Clinical Progress of ONS-5010 On Track-
Therapeutics expects to report pivotal safety and efficacy data in the third calendar quarter of 2021.
finance.yahoo.com/news/outlook-therapeutics-recent-financing-secures-140500625.html
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.